These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2111331)

  • 1. Encainide and metabolites analysis in serum or plasma using a reversed-phase high-performance liquid chromatographic technique.
    Dasgupta A; Rosenzweig IB; Turgeon J; Raisys VA
    J Chromatogr; 1990 Mar; 526(1):260-5. PubMed ID: 2111331
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of encainide and its metabolites by high-performance liquid chromatography.
    Selinger K; Crawhall JC
    J Pharm Biomed Anal; 1989; 7(3):355-9. PubMed ID: 2518704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of encainide and its three major metabolites in plasma by column liquid chromatography.
    Poirier JM; Lebot M; Cheymol G
    J Chromatogr; 1990 Dec; 534():223-7. PubMed ID: 2128839
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of encainide and metabolites in plasma and urine by high-performance liquid chromatography.
    Bartek MJ; Mayol RF; Boarman MP; Gammans RE; Gallo DG
    Ther Drug Monit; 1988; 10(4):446-52. PubMed ID: 3144068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids.
    Turgeon J; Funck-Brentano C; Gray HT; Roden DM
    J Chromatogr; 1989 May; 490(1):165-74. PubMed ID: 2503530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of enantiomers of the antiarrhythmic drug encainide and its major metabolites by chiral derivatization and high-performance liquid chromatography.
    Prakash C; Jajoo HK; Blair IA; Mayol RF
    J Chromatogr; 1989 Sep; 493(2):325-35. PubMed ID: 2511218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-performance liquid chromatographic method for the determination of encainide and its major metabolites in urine and serum using solid-phase extraction.
    Kazierad DJ; Hoon TJ; Bottorff MB
    Ther Drug Monit; 1989; 11(3):327-31. PubMed ID: 2499083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
    Harrison DC; Kates RE; Quart BD
    Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolite cumulation during long-term oral encainide administration.
    Kates RE; Harrison DC; Winkle RA
    Clin Pharmacol Ther; 1982 Apr; 31(4):427-32. PubMed ID: 6800679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enantioselective metabolism of encainide by rat liver microsomes.
    Jajoo HK; Prakash C; Mayol RF; Blair IA
    Biochem Pharmacol; 1990 Aug; 40(4):893-5. PubMed ID: 2117457
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
    Winkle RA; Peters F; Kates RE; Harrison DC
    Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical importance of metabolites of antiarrhythmic drugs.
    Kates RE; Woosley RL; Harrison DC
    Am J Cardiol; 1984 Jan; 53(1):248-51. PubMed ID: 6419577
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of encainide.
    Jaillon P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay of tocainide in blood by high-pressure liquid chromatography.
    Wolshin EM; Cavanaugh MH; Manion CV; Meyer MB; Milano E; Reardon CR; Wolshin SM
    J Pharm Sci; 1978 Dec; 67(12):1692-5. PubMed ID: 722482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog.
    Latini R; Gillis AM; Kates RE
    J Cardiovasc Pharmacol; 1984; 6(4):663-7. PubMed ID: 6206322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of encainide and metabolizer phenotype on ventricular conduction during exercise.
    Karalis DG; Nydegger C; Porter RS; Carver J; Pina IL; Kutalek SP; Michelson EL
    Am J Cardiol; 1990 Dec; 66(19):1393-6. PubMed ID: 2123075
    [No Abstract]   [Full Text] [Related]  

  • 18. Encainide for cardiac arrhythmias.
    Med Lett Drugs Ther; 1987 May; 29(740):50-2. PubMed ID: 2437434
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolites of antiarrhythmic drugs: are they clinically important?
    Kates RE
    Ration Drug Ther; 1986 May; 20(5):1-5. PubMed ID: 3097754
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.
    Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR
    J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.